[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","hv009ncxblt2cqesfbnt5dwiu","revision",2,"title","Satellos Bioscience 获得 Forazapadin 物质组成专利","originalTitle","6-K - Satellos Bioscience Inc. (0001421642) (Filer)","summary","Satellos Bioscience Inc. 在提交的 Form 6-K 中列出一份公告：公司获得 Forazapadin 物质组成专利。该文件于 10 月提交，所附公告列为 Exhibit 99.1。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-05T11:00:06.000Z","discoveredAt","2026-10-05T11:18:54.953Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",24,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fRQITkaEhVVI",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","d7033d5b-9528-4c9b-adb9-3845440fb4a1","Satellos获forazapadin物质组成专利",{"_72":73,"_15":74},"zh","

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-43107

SATELLOS BIOSCIENCE INC.
(Translation of registrant's name into English)

15 Allstate Parkway, Suite 600, Markham,
Ontario, Canada L3R 5B4
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Exhibit		Description

99.1		Satellos Granted Composition of Matter Patent for Forazapadin

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		SATELLOS BIOSCIENCE INC.
		(Registrant)


Date: October 5, 2026		/s/ Elizabeth Williams, CPA, CA
		Elizabeth Williams, CPA, CA
		Chief Financial Officer

","zhKind","complete","MSLE","公司与财报","其他","aihot","/items/hv009ncxblt2cqesfbnt5dwiu","https://www.sec.gov/Archives/edgar/data/1421642/000117184326006380/0001171843-26-006380-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791417600&sig=18cddd50281c55e6","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791417600&sig=6c66a0408e1695ad 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791417600&sig=11363acd4f484981 96w","changelogVersion","2026-10-01T08:00"]